Trial Profile

A phase 2 trial of DVX201 in high-risk patients hospitalized with viral respiratory infections

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DVX 201 (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

08 Jan 2024 New trial record
04 Jan 2024 According to a Coeptis Therapeutics media release, based on the favorable results of phase 1 investigating DVX201 in patients with hospitalized COVID-19 infection company plans to pursue a Phase 2 clinical program, allowing the company to expand beyond COVID-19 related infection and into a substantially larger patient population.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com